Simplifying Global Compliance
FDAnews Drug Daily Bulletin
Avastin Touted Over Long Term for NSCLC
April 25, 2012
Carefully selected patients with non-small cell lung cancer (NSCLC) achieved a median overall survival of 31 months with first-line chemotherapy with bevacizumab, followed by long-term bevacizumab maintenance.
Copyright ©2017. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing